Search results
Showing 4621 to 4635 of 8212 results
Recommendation ID CG146/3 Question FRAX and QFracture in adults with secondary causes of osteoporosis:- What is the utility of FRAX and
Recommendation ID NG142/3 Question What are the benefits of planned, regular community-based reviews compared with as-required review of
Recommendation ID NG203/9 Question Frequency of monitoring: For adults, children and young people with CKD, what is the optimal monitoring
Frequency of monitoring:- How frequently should children be measured to identify faltering growth?
Recommendation ID NG75/4 Question Frequency of monitoring:- How frequently should children be measured to identify faltering growth?
Recommendation ID NG20/5 Question Frequency of monitoring:- What is the effectiveness of more frequent monitoring compared with monitoring
Recommendation ID NG82/4 Question Frequency of monitoring:- What is the long-term cost effectiveness, in terms of patient-relevant outcomes
Recommendation ID NG203/12 Question Frequency of review: What is the most clinical and cost-effective frequency of review for children
Recommendation ID NG24/4 Question Fresh frozen plasma for patients with abnormal haemostasis who are having invasive procedures or surgery:-
Recommendation ID NG216/01 Question Needs assessment: From the perspective of everyone involved, what is the acceptability of strengths
Recommendation ID NG216/02 Question Risk assessment: From the perspective of everyone involved, what works well and could be improved about
Recommendation ID NG1/3 Question In infants, children and young people with overt or occult reflux, is fundoplication effective in reducing
Recommendation ID TA235/2 Question Further collection of quality of life data from people who are cured and who have experience of amputation
Recommendation ID CG115/6 Question For people with alcohol dependence, which medication is most likely to improve adherence and thereby
Recommendation ID NG203/19 Question Antiplatelet therapy: For people with CKD at the highest risk of cardiovascular disease, what is the
Recommendation ID NG230/04 Question Duration of thyroid stimulating hormone suppression: For people with differentiated thyroid cancer